Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan in Patients With Erythrocytosis by EPAS1, EGLN1, or VHL Mutations
NCT07895966Phase 2Not yet recruiting
- Sponsor
- University of Utah
- Start
- Oct 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 2 trial of belzutifan in Erythrocytosis, sponsored by University of Utah. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
belzutifan
03
Conditions
Erythrocytosis
Beyond the preview
Go deeper on NCT07895966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07895966.